Sandoz Japan launches valsartan, the first authorized generic ARB in Japan. Sandoz also launches authorized generic of Zometa® for i.v. infusion 4mg/5mL and generic version of Preminent® Tablets LD
Tokyo, June 20, 2014 Sandoz announces today the launch in Japan of three new products, including valsartan, a generic version of Novartis’ Diovan® Tablets, zoledronic acid, a generic version of Novartis’ Zometa® for i.v. infusion 4mg/5mL and Losarhyd (losartan potassium/hydrochlorothiazide), a generic version of MSD’s Preminent® Tablets LD.
Valsartan and Losarhyd are indicated for the treatment of hypertension. Zoledronic Acid is indicated for the treatment of hypercalcemia of malignancy.
“We are pleased to launch three new products including two authorized generics in the Japanese market today, further expanding Sandoz’s portfolio of high-quality, affordable medicines,” said Junichi Nakamichi, Country Head of Sandoz Japan.
For added convenience and safety, the press through package sheet for Valsartan and Losarhyd include the product information very clearly, including name, strength and indication.
The foregoing release contains forward-looking statements that can be identified by terminology such as “launches,” “launch,” or similar expressions, or by express or implied discussions regarding potential new indications or labeling for Valsartan, Losarhyd and Zoledronic Acid or regarding potential future revenues from Valsartan, Losarhyd and Zoledronic Acid. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Valsartan, Losarhyd and Zoledronic Acid to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Valsartan, Losarhyd and Zoledronic Acid will achieve any particular levels of revenue in the future. In particular, management’s expectations Valsartan, Losarhyd and Zoledronic Acid could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; uncertainties regarding actual or potential legal proceedings, including, among others, intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling Valsartan, Losarhyd and Zoledronic Acid, and the uncertain outcome of any such litigation; the particular prescribing preferences of physicians and patients; competition in general; government, industry and general public pricing pressures; unexpected manufacturing difficulties or delays; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sandoz is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees and its products are available in more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).